01:13 PM EDT, 09/27/2024 (MT Newswires) -- AbbVie ( ABBV ) submitted a biologics license application to the US Food and Drug Administration for accelerated approval of telisotuzumab vedotin to treat adult patients with previously treated, locally advanced or metastatic non-small cell lung cancer.

The submission is based on data from a phase 2 trial, the company said Friday in a statement.

Teliso-V is investigational antibody-drug conjugate aiming to target c-Met overexpressing tumors and hasn't been approved yet by any regulatory authority, AbbVie ( ABBV ) said.

AbbVie ( ABBV ) shares rose 1.6% in recent Friday trading.

Price: 194.91, Change: +3.01, Percent Change: +1.57